A CML Patient Weighs in on an "Area of Confusion"

News
Article

An issue causing a lot of confusion among oncologists and their patients is Polymerase Chain Reaction (PCR) testing, and specifically, how the results are reported and interpreted.

I'd like to suggest a topic for discussion that is causing a lot of confusion among oncologists and their patients: Polymerase Chain Reaction (PCR) testing, and specifically, how the results are reported and interpreted. This may sound like a mundane issue, but oncologists are being confused by changes in PCR test reporting, which is leading them to inadvertently giving their patients negatively skewed prognoses. I have seen this many times on the L&LS Discussion Board "Living with CML Leukemia". 

PCR testing has been used for years to determine remission status (or lack of) in leukemia patients. Labs around the world have used different equipment and standards, so PCR results have not been considered comparable between labs. In the past few years there has been a move to standardize PCR reporting for CML leukemia based on an "International Standard" for log reductions.

As this changeover is in the middle of implementation, it is causing confusion since there are many oncologists who do not understand the changeover. So, many patients are also being confused, and even told they are losing remission status, when it is simply the new reporting that has changed the numbers.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
Related Content